Anis Yohana Chaerunisaa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Anis Yohana Chaerunisaa has a total of 140 co-authors. Here are the top co-authors by number of shared publications:
- Muhaimin Muhaimin
Department of Pharmaceutical Biology, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor, 45363, Indonesia
20 shared publications - Yoga Windhu Wardhana
Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang 45363, Indonesia
10 shared publications - Iyan Sopyan
Padjadjaran University, Sumedang, Indonesia
7 shared publications Mayang Kusuma Dewi
Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, West Java, Indonesia
6 shared publications- Mayang Kusuma Dewi
Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang 45363, Indonesia
6 shared publications - Miski Aghnia Khairinisa
Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor, 45363, Indonesia
6 shared publications
Latest Publications
- Open Access
- 1 November 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-20
Micro- and Nanoparticle-Based Delivery Systems for Extract Combinations: Assessing the Synergistic Potential in Diabetes Treatment
Solid micro- and nanoparticulate delivery systems have attracted increasing interest as strategies to improve the delivery of herbal extract combinations for diabetes management. This review critically examines formulation approaches, physicochemical characteristics, encapsulation performance, antidiabetic activities, and evidence of synergistic or complementary interactions among co-delivered bioactive compounds. Relevant studies investigating solid micro- and nanoparticulate systems containing combinations of herbal extracts or herbal extracts with purified phytochemicals were evaluated, with particular attention to formulation performance, biological effects, and translational limitations. These delivery systems may improve phytochemical stability, protect bioactive constituents from degradation, and modulate release profiles. Reported antidiabetic effects include the regulation of glucose metabolism, inhibition of carbohydrate-digesting enzymes, modulation of oxidative stress and inflammatory pathways, and protection of pancreatic β-cells. However, enhanced biological activity following encapsulation does not necessarily establish pharmacological synergy, as the observed effects may also reflect additive or complementary interactions, improved compound delivery, or intrinsic carrier activity. Furthermore, the available evidence is predominantly preclinical, and human evidence specifically evaluating particulate delivery of herbal extract combinations remains limited. Important challenges include botanical and formulation standardization, carrier-related safety, long-term toxicity, biodistribution, manufacturing reproducibility, scalability, and regulatory requirements. Overall, solid micro- and nanoparticulate delivery systems offer promising formulation strategies for herbal extract combinations, but their therapeutic potential requires further validation through rigorous interaction studies, pharmacokinetic and safety assessments, and appropriately designed clinical trials. An infographic of herbal extract combinations, micro and nanoparticle delivery, anti-diabetic mechanisms, outcomes.A) Heading: COMBINATION OF HERBAL EXTRACTS. List: Extract A; Extract B; Extract C; Extract D;. B) Heading: SOLID MICRO- AND NANOPARTICLE DELIVERY SYSTEMS. Central labeled parts: Targeting Ligand; PEG Chain; Biodegradable Polymeric Matrix; Encapsulated Phytochemicals; Lipid Anchor. Size labels: Nanoparticle (10 to 200 nm); Microparticle (1 to 100 micrometers). Text: Enhanced stability, protection from degradation & controlled release. C) Heading: SYNERGISTIC ANTI-DIABETIC MECHANISMS. Items: down arrow Blood glucose levels; down arrow Carbohydrate-digesting enzymes (a-glucosidase, a-amylase); up arrow Protection of pancreatic beta-cells; down arrow Antioxidant & anti-inflammatory effects; up arrow Improved insulin sensitivity. Text: Synergistic interaction of multiple bioactives leads to enhanced efficacy. D) Heading: IMPROVED THERAPEUTIC OUTCOMES. Items: Better glycemic control; Reduced risk of diabetic complication; Safer, natural and effective alternative; Improved quality of life. Banner text: KEY ADVANTAGES OF SOLID MICRO- AND NANOPARTICULATE SYSTEMS. Items: Enhanced stability; Targeted delivery; Improved bioavailability; Controlled release; Natural and safe. Arrow key: up arrow Increase or enhancement; down arrow Decrease or reduction. Text: Solid micro- and nanoparticulate delivery systems of extract combinations are a promising strategy for effective and safe diabetes management through synergistic natural bioactives.
- 1 November 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-20
Open AccessMicro- and Nanoparticle-Based Delivery Systems for Extract Combinations: Assessing the Synergistic Potential in Diabetes Treatment
Solid micro- and nanoparticulate delivery systems have attracted increasing interest as strategies to improve the delivery of herbal extract combinations for diabetes management. This review critically examines formulation approaches, physicochemical characteristics, encapsulation performance, antidiabetic activities, and evidence of synergistic or complementary interactions among co-delivered bioactive compounds. Relevant studies investigating solid micro- and nanoparticulate systems containing combinations of herbal extracts or herbal extracts with purified phytochemicals were evaluated, with particular attention to formulation performance, biological effects, and translational limitations. These delivery systems may improve phytochemical stability, protect bioactive constituents from degradation, and modulate release profiles. Reported antidiabetic effects include the regulation of glucose metabolism, inhibition of carbohydrate-digesting enzymes, modulation of oxidative stress and inflammatory pathways, and protection of pancreatic β-cells. However, enhanced biological activity following encapsulation does not necessarily establish pharmacological synergy, as the observed effects may also reflect additive or complementary interactions, improved compound delivery, or intrinsic carrier activity. Furthermore, the available evidence is predominantly preclinical, and human evidence specifically evaluating particulate delivery of herbal extract combinations remains limited. Important challenges include botanical and formulation standardization, carrier-related safety, long-term toxicity, biodistribution, manufacturing reproducibility, scalability, and regulatory requirements. Overall, solid micro- and nanoparticulate delivery systems offer promising formulation strategies for herbal extract combinations, but their therapeutic potential requires further validation through rigorous interaction studies, pharmacokinetic and safety assessments, and appropriately designed clinical trials. An infographic of herbal extract combinations, micro and nanoparticle delivery, anti-diabetic mechanisms, outcomes.A) Heading: COMBINATION OF HERBAL EXTRACTS. List: Extract A; Extract B; Extract C; Extract D;. B) Heading: SOLID MICRO- AND NANOPARTICLE DELIVERY SYSTEMS. Central labeled parts: Targeting Ligand; PEG Chain; Biodegradable Polymeric Matrix; Encapsulated Phytochemicals; Lipid Anchor. Size labels: Nanoparticle (10 to 200 nm); Microparticle (1 to 100 micrometers). Text: Enhanced stability, protection from degradation & controlled release. C) Heading: SYNERGISTIC ANTI-DIABETIC MECHANISMS. Items: down arrow Blood glucose levels; down arrow Carbohydrate-digesting enzymes (a-glucosidase, a-amylase); up arrow Protection of pancreatic beta-cells; down arrow Antioxidant & anti-inflammatory effects; up arrow Improved insulin sensitivity. Text: Synergistic interaction of multiple bioactives leads to enhanced efficacy. D) Heading: IMPROVED THERAPEUTIC OUTCOMES. Items: Better glycemic control; Reduced risk of diabetic complication; Safer, natural and effective alternative; Improved quality of life. Banner text: KEY ADVANTAGES OF SOLID MICRO- AND NANOPARTICULATE SYSTEMS. Items: Enhanced stability; Targeted delivery; Improved bioavailability; Controlled release; Natural and safe. Arrow key: up arrow Increase or enhancement; down arrow Decrease or reduction. Text: Solid micro- and nanoparticulate delivery systems of extract combinations are a promising strategy for effective and safe diabetes management through synergistic natural bioactives.
- Open Access
- 1 October 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-22
Exosomes Derived from Sea Cucumbers in Indonesian Marine for Anti-Aging and Skin Regeneration
Indonesia’s marine ecosystem is rich in biodiversity, including sea cucumbers that contain a range of potentially valuable bioactive compounds. Among these, exosomes—nanosized extracellular vesicles (EVs) that transport biological molecules between cells—are attracting interest as possible tools for anti-aging and skin regeneration. This review summarizes current knowledge about sea cucumber-derived exosomes and considers their potential applications in skincare and tissue repair. Sea cucumber exosomes may offer several advantages over the use of isolated compounds alone. Their vesicle structure can help protect and transport bioactive molecules, potentially supporting their delivery to target cells. Reported or proposed activities include antioxidant and anti-inflammatory effects, which may help limit oxidative stress and inflammation associated with skin aging. Exosomes may also support collagen production and skin elasticity, while promoting wound healing and tissue recovery. By influencing skin-cell communication and immune responses, they can contribute to a more coordinated regenerative process. These properties make sea cucumber exosomes a promising subject for research into multifunctional skincare approaches. Their potential use also highlights the value of Indonesia’s marine resources and may encourage the development of locally sourced, nature-based products. However, sustainability depends on responsible harvesting and processing, and further research is needed to establish exosome composition, production methods, safety, efficacy, and long-term effects. In particular, laboratory findings must be validated through well-designed clinical studies before therapeutic or cosmetic claims can be confirmed. Overall, sea cucumber-derived exosomes from Indonesian marine ecosystems represent a promising area of research for anti-aging and skin regeneration. Their potential combination of bioactive cargo, cellular delivery, and regenerative effects may inform future skincare products and therapies, provided that development is supported by rigorous evidence and environmentally responsible practices.
- 1 October 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-22
Open AccessExosomes Derived from Sea Cucumbers in Indonesian Marine for Anti-Aging and Skin Regeneration
Indonesia’s marine ecosystem is rich in biodiversity, including sea cucumbers that contain a range of potentially valuable bioactive compounds. Among these, exosomes—nanosized extracellular vesicles (EVs) that transport biological molecules between cells—are attracting interest as possible tools for anti-aging and skin regeneration. This review summarizes current knowledge about sea cucumber-derived exosomes and considers their potential applications in skincare and tissue repair. Sea cucumber exosomes may offer several advantages over the use of isolated compounds alone. Their vesicle structure can help protect and transport bioactive molecules, potentially supporting their delivery to target cells. Reported or proposed activities include antioxidant and anti-inflammatory effects, which may help limit oxidative stress and inflammation associated with skin aging. Exosomes may also support collagen production and skin elasticity, while promoting wound healing and tissue recovery. By influencing skin-cell communication and immune responses, they can contribute to a more coordinated regenerative process. These properties make sea cucumber exosomes a promising subject for research into multifunctional skincare approaches. Their potential use also highlights the value of Indonesia’s marine resources and may encourage the development of locally sourced, nature-based products. However, sustainability depends on responsible harvesting and processing, and further research is needed to establish exosome composition, production methods, safety, efficacy, and long-term effects. In particular, laboratory findings must be validated through well-designed clinical studies before therapeutic or cosmetic claims can be confirmed. Overall, sea cucumber-derived exosomes from Indonesian marine ecosystems represent a promising area of research for anti-aging and skin regeneration. Their potential combination of bioactive cargo, cellular delivery, and regenerative effects may inform future skincare products and therapies, provided that development is supported by rigorous evidence and environmentally responsible practices.
- Open Access
- 1 September 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-24
Konjac Glucomannan as a Gel-Forming Biopolymer for Transdermal Drug Delivery: Properties, Formulation Strategies, and Translational Challenges
Konjac glucomannan is a natural polysaccharide increasingly relevant as a matrix forming material for skin applied delivery systems. Its potential is linked to its glucose and mannose backbone, abundant hydroxyl groups, partial acetyl substitution, high molecular weight, and capacity for chain association. These features regulate hydration, swelling, rheology, viscoelasticity, film formation, gelation, and drug release. This narrative review examines konjac glucomannan from a structure based formulation perspective, covering physicochemical attributes, modification strategies, formulation platforms, release behavior, and evaluation requirements. Unlike previous reviews that broadly discuss polysaccharide based transdermal systems or glucomannan across pharmaceutical applications, this review focuses on the relationship between KGM structure, formulation design, and translational performance. Evidence shows its use in films, hydrogel reservoirs, injectable hydrogels, nanofibrous systems, carrier assisted systems, and multilayer matrices. In these platforms, konjac glucomannan functions as a hydration regulating matrix former, release modulator, and structural component. Blending, deacetylation, oxidation, crosslinking, freeze thaw treatment, electrospinning, and layered design can improve mechanical integrity, moisture control, and release performance. However, outcomes vary with molecular attributes, modification conditions, and evaluation methods. Most studies remain focused on material characterization and in vitro release, while durable skin adhesion, ex vivo permeation, skin deposition, long wear performance, and clinically meaningful transport are still insufficiently demonstrated. Further translation requires standardized molecular attributes, ex vivo and in vivo testing, scalable manufacturing, and regulatory evaluation.
- 1 September 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-24
Open AccessKonjac Glucomannan as a Gel-Forming Biopolymer for Transdermal Drug Delivery: Properties, Formulation Strategies, and Translational Challenges
Konjac glucomannan is a natural polysaccharide increasingly relevant as a matrix forming material for skin applied delivery systems. Its potential is linked to its glucose and mannose backbone, abundant hydroxyl groups, partial acetyl substitution, high molecular weight, and capacity for chain association. These features regulate hydration, swelling, rheology, viscoelasticity, film formation, gelation, and drug release. This narrative review examines konjac glucomannan from a structure based formulation perspective, covering physicochemical attributes, modification strategies, formulation platforms, release behavior, and evaluation requirements. Unlike previous reviews that broadly discuss polysaccharide based transdermal systems or glucomannan across pharmaceutical applications, this review focuses on the relationship between KGM structure, formulation design, and translational performance. Evidence shows its use in films, hydrogel reservoirs, injectable hydrogels, nanofibrous systems, carrier assisted systems, and multilayer matrices. In these platforms, konjac glucomannan functions as a hydration regulating matrix former, release modulator, and structural component. Blending, deacetylation, oxidation, crosslinking, freeze thaw treatment, electrospinning, and layered design can improve mechanical integrity, moisture control, and release performance. However, outcomes vary with molecular attributes, modification conditions, and evaluation methods. Most studies remain focused on material characterization and in vitro release, while durable skin adhesion, ex vivo permeation, skin deposition, long wear performance, and clinically meaningful transport are still insufficiently demonstrated. Further translation requires standardized molecular attributes, ex vivo and in vivo testing, scalable manufacturing, and regulatory evaluation.
- Open Access
- 1 August 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-2
Data Interpretation Paradoxes in a Nanoencapsulated α-Mangostin Hydrogel Film for Anti-Acne Therapy [Response to Letter]
Response to Letter in regards to Data Interpretation Paradoxes in a Nanoencapsulated α-Mangostin Hydrogel Film for Anti-Acne Therapy [Letter]
- 1 August 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-2
Open AccessData Interpretation Paradoxes in a Nanoencapsulated α-Mangostin Hydrogel Film for Anti-Acne Therapy [Response to Letter]
Response to Letter in regards to Data Interpretation Paradoxes in a Nanoencapsulated α-Mangostin Hydrogel Film for Anti-Acne Therapy [Letter]
- Open Access
- 4 July 2026
- Published by Elsevier in SSRN Electronic Journal
Impact of Adsorption-Based Solidification on the Pharmaceutical Performance and Antidyslipidemic Efficacy of Simvastatin–Ezetimibe SNEDDS
Simvastatin and ezetimibe are widely used in combination therapy for dyslipidemia; however, their poor aqueous solubility limits oral drug delivery. This study aimed to develop and characterize liquid and solid self-nanoemulsifying drug delivery systems (L-SNEDDS and S-SNEDDS) containing simvastatin and ezetimibe and to evaluate the impact of solidification on their physicochemical characteristics, dissolution behavior, and antidyslipidemic efficacy. An optimized L-SNEDDS composed of Capryol® 90, Cremophor® RH40, and Transcutol® HP was successfully converted into S-SNEDDS by adsorption onto Neusilin® US2. The optimized L-SNEDDS exhibited rapid self-emulsification, high transmittance, and a globule size of 24.47 ± 0.55 nm, whereas S-SNEDDS readily reconstituted into a nanoemulsion with a globule size of 44.60 ± 0.52 nm. Solidification did not alter the chemical integrity of either drug and resulted in both drugs being present predominantly in an amorphous or molecularly dispersed state. Both formulations markedly enhanced the apparent solubility and dissolution of simvastatin and ezetimibe compared with the drug suspension, although S-SNEDDS exhibited a modest reduction in dissolution relative to L-SNEDDS. In a Poloxamer 407-induced dyslipidemia model, both formulations significantly improved the lipid profile compared with the dyslipidemic control and produced greater lipid-lowering effects than the drug suspension, while no significant differences were observed between L-SNEDDS and S-SNEDDS. These findings demonstrate that solidification preserved the therapeutic performance of the optimized L-SNEDDS while providing the pharmaceutical advantages of a solid dosage form, supporting S-SNEDDS as a promising oral lipid-based delivery system for simvastatin–ezetimibe combination therapy.
- 4 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessImpact of Adsorption-Based Solidification on the Pharmaceutical Performance and Antidyslipidemic Efficacy of Simvastatin–Ezetimibe SNEDDS
Simvastatin and ezetimibe are widely used in combination therapy for dyslipidemia; however, their poor aqueous solubility limits oral drug delivery. This study aimed to develop and characterize liquid and solid self-nanoemulsifying drug delivery systems (L-SNEDDS and S-SNEDDS) containing simvastatin and ezetimibe and to evaluate the impact of solidification on their physicochemical characteristics, dissolution behavior, and antidyslipidemic efficacy. An optimized L-SNEDDS composed of Capryol® 90, Cremophor® RH40, and Transcutol® HP was successfully converted into S-SNEDDS by adsorption onto Neusilin® US2. The optimized L-SNEDDS exhibited rapid self-emulsification, high transmittance, and a globule size of 24.47 ± 0.55 nm, whereas S-SNEDDS readily reconstituted into a nanoemulsion with a globule size of 44.60 ± 0.52 nm. Solidification did not alter the chemical integrity of either drug and resulted in both drugs being present predominantly in an amorphous or molecularly dispersed state. Both formulations markedly enhanced the apparent solubility and dissolution of simvastatin and ezetimibe compared with the drug suspension, although S-SNEDDS exhibited a modest reduction in dissolution relative to L-SNEDDS. In a Poloxamer 407-induced dyslipidemia model, both formulations significantly improved the lipid profile compared with the dyslipidemic control and produced greater lipid-lowering effects than the drug suspension, while no significant differences were observed between L-SNEDDS and S-SNEDDS. These findings demonstrate that solidification preserved the therapeutic performance of the optimized L-SNEDDS while providing the pharmaceutical advantages of a solid dosage form, supporting S-SNEDDS as a promising oral lipid-based delivery system for simvastatin–ezetimibe combination therapy.
- Open Access
- 1 June 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-40
A Review of Medicinal Plants from the Anak Dalam Tribe of Jambi: An Evaluation of Their Potential for Diabetic Wound Healing Effects—Current Status and Future Perspectives
The Anak Dalam tribe, popularly known as Suku Anak Dalam (SAD), is an indigenous community in the Jambi Province of Indonesia. The traditional knowledge within this group is deeply intertwined with forest resources, particularly regarding medicinal plants utilized for wound healing. Significantly, diabetic wounds are a severe complication of diabetes mellitus. These wounds are typically characterized by delayed healing processes, high susceptibility to infection, and an elevated risk of amputation. Accordingly, this review summarizes medicinal plants traditionally employed by the Anak Dalam community for various wound-related conditions. Beyond simple documentation, the study evaluates the potential relevance of these species as candidate sources for diabetic wound-healing research. In this study, a narrative literature review was conducted utilizing databases such as Scopus, ScienceDirect, PubMed, Google Scholar, and ResearchGate, covering publications released between 2015 and 2025. Altogether, 40 medicinal plants were examined. Specifically, several species (ie, Anredera cordifolia, Centella asiatica, Psidium guajava, and Piper betle) demonstrated pharmacological activities directly relevant to wound-healing processes. The primary phytochemical constituents identified across these studies are flavonoids, alkaloids, terpenoids, saponins, and phenolic compounds. Crucially, these compounds are reported to exhibit potent antioxidant, anti-inflammatory, and antibacterial activities. Furthermore, these substances support vital biological processes associated with tissue repair, such as fibroblast proliferation, collagen synthesis, angiogenesis, and re-epithelialization. Most existing evidence, however, is derived from in vitro assays, animal models, or indirect pharmacological investigations. Therefore, the findings of this review should be viewed as a basis for generating potential candidates rather than as definitive proof of established clinical efficacy. This review highlights the necessity of integrating ethnobotanical knowledge with rigorous pharmacological validation. Ultimately, such integration is essential to support future research into evidence-based herbal approaches for the management of diabetic wounds. A diagram showing medicinal plants leads to diabetic foot ulcer with foot sore which further leads to skin cross-section.
- 1 June 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-40
Open AccessA Review of Medicinal Plants from the Anak Dalam Tribe of Jambi: An Evaluation of Their Potential for Diabetic Wound Healing Effects—Current Status and Future Perspectives
The Anak Dalam tribe, popularly known as Suku Anak Dalam (SAD), is an indigenous community in the Jambi Province of Indonesia. The traditional knowledge within this group is deeply intertwined with forest resources, particularly regarding medicinal plants utilized for wound healing. Significantly, diabetic wounds are a severe complication of diabetes mellitus. These wounds are typically characterized by delayed healing processes, high susceptibility to infection, and an elevated risk of amputation. Accordingly, this review summarizes medicinal plants traditionally employed by the Anak Dalam community for various wound-related conditions. Beyond simple documentation, the study evaluates the potential relevance of these species as candidate sources for diabetic wound-healing research. In this study, a narrative literature review was conducted utilizing databases such as Scopus, ScienceDirect, PubMed, Google Scholar, and ResearchGate, covering publications released between 2015 and 2025. Altogether, 40 medicinal plants were examined. Specifically, several species (ie, Anredera cordifolia, Centella asiatica, Psidium guajava, and Piper betle) demonstrated pharmacological activities directly relevant to wound-healing processes. The primary phytochemical constituents identified across these studies are flavonoids, alkaloids, terpenoids, saponins, and phenolic compounds. Crucially, these compounds are reported to exhibit potent antioxidant, anti-inflammatory, and antibacterial activities. Furthermore, these substances support vital biological processes associated with tissue repair, such as fibroblast proliferation, collagen synthesis, angiogenesis, and re-epithelialization. Most existing evidence, however, is derived from in vitro assays, animal models, or indirect pharmacological investigations. Therefore, the findings of this review should be viewed as a basis for generating potential candidates rather than as definitive proof of established clinical efficacy. This review highlights the necessity of integrating ethnobotanical knowledge with rigorous pharmacological validation. Ultimately, such integration is essential to support future research into evidence-based herbal approaches for the management of diabetic wounds. A diagram showing medicinal plants leads to diabetic foot ulcer with foot sore which further leads to skin cross-section.
- Open Access
- 1 June 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-49
Nanocarrier-Mediated Delivery Systems of Phytochemicals to Enhance and Accelerate Diabetic Wound Healing Processes
This review explores the mechanistic and translational potential of nanotechnology-based delivery systems for natural compounds in diabetic wound healing. Diabetic wounds present a persistent challenge due to impaired tissue regeneration and chronic inflammation. Phytochemicals such as flavonoids and polyphenols exhibit potent antioxidant, anti-inflammatory, and tissue-regenerative properties but are limited by low bioavailability and stability. Nanoparticle formulations—particularly silver nanoparticles (AgNPs) and chitosan-based nanoparticles (CNPs)—offer innovative solutions by enhancing stability, tissue penetration, and sustained release of these bioactives. Our analysis highlights how these nanocarriers facilitate targeted delivery, thereby amplifying antioxidant activity, antimicrobial effects, and tissue regeneration mechanisms critical for wound healing. The review underscores the mechanistic insights into how nanoparticle systems improve therapeutic efficacy and discusses their translational potential in clinical settings. Notably, AgNPs’ antimicrobial properties and green synthesis, along with CNPs’ biocompatibility and bioadhesive characteristics, position these nanomaterials as promising candidates for advancing diabetic wound care. This synthesis of current evidence emphasizes nanotechnology’s role in overcoming the limitations of natural compounds and advancing sustainable, effective treatments for diabetic wounds. The infographic highlights nanocarrier-mediated delivery systems for phytochemicals to improve diabetic wound healing. Polyphenols and flavonoids provide antioxidant, anti-inflammatory and antimicrobial effects but face challenges like poor bioavailability and stability. Diabetic wounds suffer from oxidative stress, chronic inflammation and infection. Nanoparticle-based systems enhance stability, bioavailability, targeted delivery and sustained release. Types include metallic (gold, silver, zinc oxide), polymeric (PLGA, chitosan, gelatin) and lipid-based nanoparticles (liposome, solid lipid). These systems offer antimicrobial, antioxidant and pro-angiogenic effects, with versatile, biocompatible properties and high bioavailability. They improve diabetic wound healing by reducing oxidative stress, modulating inflammation, controlling infection, enhancing angiogenesis and speeding tissue regeneration.An infographic on nanocarrier systems for polyphenols and flavonoids in diabetic wound healing.
- 1 June 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-49
Open AccessNanocarrier-Mediated Delivery Systems of Phytochemicals to Enhance and Accelerate Diabetic Wound Healing Processes
This review explores the mechanistic and translational potential of nanotechnology-based delivery systems for natural compounds in diabetic wound healing. Diabetic wounds present a persistent challenge due to impaired tissue regeneration and chronic inflammation. Phytochemicals such as flavonoids and polyphenols exhibit potent antioxidant, anti-inflammatory, and tissue-regenerative properties but are limited by low bioavailability and stability. Nanoparticle formulations—particularly silver nanoparticles (AgNPs) and chitosan-based nanoparticles (CNPs)—offer innovative solutions by enhancing stability, tissue penetration, and sustained release of these bioactives. Our analysis highlights how these nanocarriers facilitate targeted delivery, thereby amplifying antioxidant activity, antimicrobial effects, and tissue regeneration mechanisms critical for wound healing. The review underscores the mechanistic insights into how nanoparticle systems improve therapeutic efficacy and discusses their translational potential in clinical settings. Notably, AgNPs’ antimicrobial properties and green synthesis, along with CNPs’ biocompatibility and bioadhesive characteristics, position these nanomaterials as promising candidates for advancing diabetic wound care. This synthesis of current evidence emphasizes nanotechnology’s role in overcoming the limitations of natural compounds and advancing sustainable, effective treatments for diabetic wounds. The infographic highlights nanocarrier-mediated delivery systems for phytochemicals to improve diabetic wound healing. Polyphenols and flavonoids provide antioxidant, anti-inflammatory and antimicrobial effects but face challenges like poor bioavailability and stability. Diabetic wounds suffer from oxidative stress, chronic inflammation and infection. Nanoparticle-based systems enhance stability, bioavailability, targeted delivery and sustained release. Types include metallic (gold, silver, zinc oxide), polymeric (PLGA, chitosan, gelatin) and lipid-based nanoparticles (liposome, solid lipid). These systems offer antimicrobial, antioxidant and pro-angiogenic effects, with versatile, biocompatible properties and high bioavailability. They improve diabetic wound healing by reducing oxidative stress, modulating inflammation, controlling infection, enhancing angiogenesis and speeding tissue regeneration.An infographic on nanocarrier systems for polyphenols and flavonoids in diabetic wound healing.
- Open Access
- 25 May 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (6) , 825
Enhancing Antibacterial Activity of Medinilla speciosa Blume Fruits Against Cutibacterium acnes Through Phytosome Delivery: An In Vivo Study
Background/Objectives: The fruit of Medinilla speciosa Blume fruit contains flavonoids with potent activity against Cutibacterium acnes, but their clinical application is hindered by poor bioavailability. This study aimed to develop, characterize, and evaluate a phytosome-based vesicular system to enhance the in vivo antibacterial efficacy of the fruit’s ethyl acetate fraction (EAFMS). Methods: Phytosomes were synthesized via antisolvent precipitation using a 1:3 EAFMS-to-phospholipid ratio. Formulations were characterized for particle size, polydispersity index (PDI), zeta potential, entrapment efficiency (EE), and in vitro release. Antibacterial efficacy was assessed in C. acnes-induced Wistar rats over three days. Results: EAFMS showed superior antibacterial activity with a 93.5% relative potency compared to tetracycline. The optimized phytosomes exhibited favorable physicochemical properties: particle size of phytosome 244.60 ± 0.85 nm, PDI of phytosome 0.396 ± 0.08, zeta potensial of phytosome −56.70 ± 2.08 mV, and EE of phytosome 89.46 ± 0.45%. The formulation achieved a 76.504% cumulative release at 8 h. In vivo trials demonstrated that the phytosome cream significantly reduced bacterial colony counts and diminished inflammatory cell infiltration compared to the cream base. Conclusions: The phytosome system effectively improves the stability and delivery of M. speciosa flavonoids, significantly enhancing their antibacterial and anti-inflammatory performance against acne.
- 25 May 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (6) , 825
Open AccessEnhancing Antibacterial Activity of Medinilla speciosa Blume Fruits Against Cutibacterium acnes Through Phytosome Delivery: An In Vivo Study
Background/Objectives: The fruit of Medinilla speciosa Blume fruit contains flavonoids with potent activity against Cutibacterium acnes, but their clinical application is hindered by poor bioavailability. This study aimed to develop, characterize, and evaluate a phytosome-based vesicular system to enhance the in vivo antibacterial efficacy of the fruit’s ethyl acetate fraction (EAFMS). Methods: Phytosomes were synthesized via antisolvent precipitation using a 1:3 EAFMS-to-phospholipid ratio. Formulations were characterized for particle size, polydispersity index (PDI), zeta potential, entrapment efficiency (EE), and in vitro release. Antibacterial efficacy was assessed in C. acnes-induced Wistar rats over three days. Results: EAFMS showed superior antibacterial activity with a 93.5% relative potency compared to tetracycline. The optimized phytosomes exhibited favorable physicochemical properties: particle size of phytosome 244.60 ± 0.85 nm, PDI of phytosome 0.396 ± 0.08, zeta potensial of phytosome −56.70 ± 2.08 mV, and EE of phytosome 89.46 ± 0.45%. The formulation achieved a 76.504% cumulative release at 8 h. In vivo trials demonstrated that the phytosome cream significantly reduced bacterial colony counts and diminished inflammatory cell infiltration compared to the cream base. Conclusions: The phytosome system effectively improves the stability and delivery of M. speciosa flavonoids, significantly enhancing their antibacterial and anti-inflammatory performance against acne.
- Open Access
- 1 May 2026
- Published by Taylor & Francis in Therapeutics and Clinical Risk Management
- Vol. ume 22, 1-14
Adjunctive Cannabidiol for Drug-Resistant Epilepsy: A Systematic Review and Meta-Analysis of Randomized Trials Across Syndromes, Formulations, and Dose Ranges
Cannabidiol (CBD) has emerged as a promising adjunctive therapy for drug-resistant epilepsy, yet clinical findings remain heterogeneous across trials. This meta-analysis aimed to evaluate the efficacy, safety, and formulation-dependent performance of CBD in patients with treatment-resistant epilepsies. A systematic review and meta-analysis were conducted in accordance with PRISMA 2020 guidelines, including randomized, double-blind, placebo-controlled trials of adjunctive CBD in drug-resistant epilepsy. Literature was sourced from PubMed/MEDLINE, Scopus, and the Cochrane Central Register of Controlled Trials (CENTRAL). Data were synthesized using random-effects models to estimate pooled risk ratios (RRs) with 95% confidence intervals (CIs) for seizure reduction and adverse events. Subgroup analyses explored the influence of epilepsy syndrome, CBD dose, and formulation type. Seven randomized controlled trials involving 1154 participants met inclusion criteria. Adjunctive CBD significantly reduced seizure frequency compared with placebo (pooled RR = 0.72, 95% CI 0.71–0.73; p < 0.0001). The effect was consistent across Dravet syndrome, Lennox–Gastaut syndrome, and tuberous sclerosis complex, with optimal efficacy observed at 20 mg/kg per day of highly purified oral CBD. Liposomal CBD produced modest benefit, whereas transdermal formulations showed no short-term efficacy. Adverse events were predominantly mild and comparable to placebo, although elevations in hepatic enzymes and somnolence occurred more frequently in patients receiving concomitant valproate or clobazam. Adjunctive oral CBD provides a reproducible and clinically meaningful reduction in seizures in drug-resistant epilepsy, with an acceptable safety profile. Oral CBD at 20 mg/kg per day represents the current benchmark for efficacy, while alternative formulations require further evaluation. Future research should address long-term outcomes, optimal dosing strategies, and formulation refinement to improve tolerability and accessibility in diverse epileptic populations.
- 1 May 2026
- Published by Taylor & Francis in Therapeutics and Clinical Risk Management
- Vol. ume 22, 1-14
Open AccessAdjunctive Cannabidiol for Drug-Resistant Epilepsy: A Systematic Review and Meta-Analysis of Randomized Trials Across Syndromes, Formulations, and Dose Ranges
Cannabidiol (CBD) has emerged as a promising adjunctive therapy for drug-resistant epilepsy, yet clinical findings remain heterogeneous across trials. This meta-analysis aimed to evaluate the efficacy, safety, and formulation-dependent performance of CBD in patients with treatment-resistant epilepsies. A systematic review and meta-analysis were conducted in accordance with PRISMA 2020 guidelines, including randomized, double-blind, placebo-controlled trials of adjunctive CBD in drug-resistant epilepsy. Literature was sourced from PubMed/MEDLINE, Scopus, and the Cochrane Central Register of Controlled Trials (CENTRAL). Data were synthesized using random-effects models to estimate pooled risk ratios (RRs) with 95% confidence intervals (CIs) for seizure reduction and adverse events. Subgroup analyses explored the influence of epilepsy syndrome, CBD dose, and formulation type. Seven randomized controlled trials involving 1154 participants met inclusion criteria. Adjunctive CBD significantly reduced seizure frequency compared with placebo (pooled RR = 0.72, 95% CI 0.71–0.73; p < 0.0001). The effect was consistent across Dravet syndrome, Lennox–Gastaut syndrome, and tuberous sclerosis complex, with optimal efficacy observed at 20 mg/kg per day of highly purified oral CBD. Liposomal CBD produced modest benefit, whereas transdermal formulations showed no short-term efficacy. Adverse events were predominantly mild and comparable to placebo, although elevations in hepatic enzymes and somnolence occurred more frequently in patients receiving concomitant valproate or clobazam. Adjunctive oral CBD provides a reproducible and clinically meaningful reduction in seizures in drug-resistant epilepsy, with an acceptable safety profile. Oral CBD at 20 mg/kg per day represents the current benchmark for efficacy, while alternative formulations require further evaluation. Future research should address long-term outcomes, optimal dosing strategies, and formulation refinement to improve tolerability and accessibility in diverse epileptic populations.
- Open Access
- 1 May 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-29
Protection of Hygroscopic Pharmaceutical and Nutraceutical Active Ingredients via Film Coating Technologies: A Review
Hygroscopicity poses a significant challenge in the formulation of pharmaceutical and nutraceutical products, as moisture absorption often leads to chemical degradation, physical instability, and compromised therapeutic efficacy. This narrative literature review, evaluated the comparative effectiveness of various polymeric systems and coating technologies as moisture barriers across diverse dosage forms, including tablets, powders, granules, and particulates. We analyzed a spectrum of barrier materials, including cellulose derivatives, polyvinylpyrrolidone, polyvinyl alcohol (PVA), methacrylates, and shellac, contrasting conventional solvent based techniques (fluid bed, spray drying, freeze drying coating) with advanced methodologies (hot melt coating, electrostatic dry coating, and Atomic Layer Deposition/ALD). Conventional coating systems utilizing HPMC and PVA were found to maintain moisture uptake below 1.5% during long-term storage (40°C/75% RH). However, more advanced strategies demonstrated superior protective capabilities, for instance, hotmelt coating employing lipid-based excipients (Precirol ATO 5) reduced moisture absorption by up to 85% at 75% RH. Furthermore, electrostatic dry coating showed a significant reduction in weight gain, decreasing from 6.5% to 3.3% compared to uncoated cores over a 48-hour period. Notably, ALD provided the most robust protection, preserving the amorphous stability of sensitive particles for up to two years under extreme conditions. This review highlights that film coatings not only mitigate moisture induced degradation but also enhance shelf life and improve the mechanical properties of dosage forms. These results underscore the versatility of coating technologies, enabling formulators to tailor strategies for highly moisture sensitive compounds.
- 1 May 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-29
Open AccessProtection of Hygroscopic Pharmaceutical and Nutraceutical Active Ingredients via Film Coating Technologies: A Review
Hygroscopicity poses a significant challenge in the formulation of pharmaceutical and nutraceutical products, as moisture absorption often leads to chemical degradation, physical instability, and compromised therapeutic efficacy. This narrative literature review, evaluated the comparative effectiveness of various polymeric systems and coating technologies as moisture barriers across diverse dosage forms, including tablets, powders, granules, and particulates. We analyzed a spectrum of barrier materials, including cellulose derivatives, polyvinylpyrrolidone, polyvinyl alcohol (PVA), methacrylates, and shellac, contrasting conventional solvent based techniques (fluid bed, spray drying, freeze drying coating) with advanced methodologies (hot melt coating, electrostatic dry coating, and Atomic Layer Deposition/ALD). Conventional coating systems utilizing HPMC and PVA were found to maintain moisture uptake below 1.5% during long-term storage (40°C/75% RH). However, more advanced strategies demonstrated superior protective capabilities, for instance, hotmelt coating employing lipid-based excipients (Precirol ATO 5) reduced moisture absorption by up to 85% at 75% RH. Furthermore, electrostatic dry coating showed a significant reduction in weight gain, decreasing from 6.5% to 3.3% compared to uncoated cores over a 48-hour period. Notably, ALD provided the most robust protection, preserving the amorphous stability of sensitive particles for up to two years under extreme conditions. This review highlights that film coatings not only mitigate moisture induced degradation but also enhance shelf life and improve the mechanical properties of dosage forms. These results underscore the versatility of coating technologies, enabling formulators to tailor strategies for highly moisture sensitive compounds.